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Introduction
Drug-induced liver injury (DILI) manifests as a spectrum of 
clinical presentations that carries morbidity and mortality 
(1). The liver places a prime target for reactive metabolites 
of medicines as is central to removal of lipophilic drugs 
and presence of specific enzyme disposal pathway(s) of 
biotransformation (metabolism) (2). Establish the 
frequency of DILI worldwide associated with the clinical 
use of drugs is challenge due lack of consistent reporting 
systems and definitions (3). Thought, there is the 
acquiescence of increasing frequency of hepatic drug 
reactions due to the rise of prescriptions and the number 
of pharmacological agents available (4, 5).
Liver toxicity related to drugs have been divided into two 
varieties, based on the presumed mechanism of action of 
the chemical compound: intrinsic (direct or predictable) 
and idiosyncratic (indirect or unpredictable) (3).  After the 
exposure to reactive metabolites, there are organelle 
stress and inflammation, resulting in necrosis and/or 
apoptosis of the hepatocyte or the induction of adaptive 
responses, with injury not occurring or being very mild. In 
the intrinsic DILI the process is determined by the 
individual drug and the hosts factors (especially genetic), 
with the role of innate and adaptive immune system (6). 
Intrinsic DILI is typically dose-related, onset is within a 
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Abstract
Introduction and aim: Drug-induced liver injury (DILI) manifests as a spectrum of clinical presentations 
that carries morbidity and mortality. Patients with chronic liver disease (CLD), particularly hospitalized, are 
at high risk for developing DILI. We aimed to investigate the use of potentially hepatotoxic drugs (PHD) in 
patients with CLD in a tertiary university hospital. Materials and methods: Adult (≥ 18 years-old) with CLD 
admitted to the hospital from January 2016 to December 2018 were evaluated regarding PHD, assessing 
the risk of DILI and liver enzymes behavior after exposure. Results: From 931 hospitalized patients with 
CLD, 291 (31.3%) were exposed to hepatotoxic drugs during their hospitalization.  Of those, 244 (83.8%) 
were cirrhotic. The most frequent causes of liver disease were hepatitis C (41.2%), followed by alcohol 
(13.2%), hepatitis C/alcohol (11.7%) and non-alcoholic fatty liver disease (5.8%). Decompensated 
cirrhosis (46.7%) was the main reason for hospital admission. The most often prescribed PHD were 
antibiotics (67.7%), cardiovascular drugs (34.4%), neuromodulators (26.1%) and anesthetics (19.9%). 
After exposure, 113 patients (38.8%) presented significant elevated liver enzymes. Surprisingly, PHD 
were more often prescribed in GI/Liver unit (48.8%) followed by emergency/intensive care unit (28.5%). A 
total of 65 patients (22%) died, however in neither case was it possible to safely infer causal relationship 
among PHD, liver enzymes and death. Conclusion: PHD prescription is frequent in patients with CLD 
even in a tertiary university hospital and in the gastroenterology and hepatology department, exposing 
these patients to an additional risk.  
Keywords: liver diseases, drug-induced liver injury, acute-on-chronic liver failure, acute liver failure.
Resumen
Introducción y objetivo: La lesión hepática inducida por fármacos (DILI) se manifiesta como un espectro 
de presentaciones clínicas que conlleva morbilidad y mortalidad. Los pacientes con enfermedad hepática 
crónica (EHC), en particular hospitalizados, tienen un alto riesgo de desarrollar DILI. Nuestro objetivo fue 
investigar el uso de fármacos potencialmente hepatotóxicos (FPH) en pacientes con EHC en un hospital 
universitario terciario. Materiales y métodos: Se evaluó la expossición a  FPH en adultos (≥ 18 años) con 
EHC ingresados en el hospital entre enero de 2016 y diciembre de 2018, evaluando el riesgo de DILI y el 
comportamiento de las enzimas hepáticas tras la exposición. Resultados: De 931 pacientes 
hospitalizados con EHC, 291 (31,3%) estuvieron expuestos a fármacos hepatotóxicos durante su 
hospitalización. De ellos, 244 (83,8%) eran cirróticos. Las causas más frecuentes de enfermedad 
hepática fueron la hepatitis C (41,2%), seguida del alcohol (13,2%), la hepatitis C / alcohol (11,7%) y la 
enfermedad del hígado graso no alcohólico (5,8%). La cirrosis descompensada (46,7%) fue el principal 
motivo de ingreso hospitalario. Los FPH más prescritos fueron antibióticos (67,7%), fármacos 
cardiovasculares (34,4%), neuromoduladores (26,1%) y anestésicos (19,9%). Tras la exposición, 113 
pacientes (38,8%) presentaron elevación significativa de las enzimas hepáticas. Sorprendentemente, los 
FPH se prescribieron con mayor frecuencia en la unidad GI / Hígado (48,8%) seguido de la unidad de 
emergencia / cuidados intensivos (28,5%). Un total de 65 pacientes (22%) fallecieron, sin embargo, en 
ninguno de los casos fue posible inferir con seguridad la relación causal entre el FHD, las enzimas 
hepáticas y la muerte. Conclusión: la prescripción de FPH es frecuente en pacientes con EHC incluso en 
un hospital universitario terciario y en el servicio de gastroenterología y hepatología, exponiendo a estos 
pacientes a un riesgo adicional.
Palabras clave: enfermedad hepática, lesión hepática inducida por fármacos, insuficiencia hepática 
aguda sobre crónica, insuficiencia hepática aguda.
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short time span (hours to days), while idiosyncratic is 
usually not dose-related, and has a longer latency period 
(3).
Cirrhosis and chronic liver disease (CLD) not necessarily 
increases the risk of developing DILI (7, 8), however it is 
known based on systematic review of cohort studies that 
chronic hepatitis B and C are  risk factors for DILI caused 
by anti- human immunodeficiency virus and anti-
tuberculostatic therapy (9). Furthermore, DILI in patients 
with underlying liver disease arouse higher mortality (4). In 
cirrhotic patients most medications have not been 
thoroughly studied and specific prescribing information is 
often lacking; in those patients lower doses of medication 
are generally recommended based on pharmacokinetic 
change, despite limited data also in that subject (10). Acute 
hepatic lesion caused by drugs has been reported 
between 2% and 10% of patients hospitalized for jaundice 
(8). Hospitalized CLD patients are at high risk for 
developing DILI, however among those patients there is 
scant information on the pattern of medical prescription 
(10).
The diagnostic of DILI is a challenge for physicians, due 
the heterogeneous phenotypes (mild increase of liver 
enzymes (cholestatic, hepatocellular and mixed) to acute 
liver failure (ALF), absence of specific biomarkers and the 
need for diagnosis exclusion) (9). The greatest difficulty in 
research on DILI in patients with underlying liver disease is 
the distinction between additional liver injury caused by a 
medicine or progression of the underlying liver disease. 
Add to that the is sparing information on the pattern of 
potential hepatotoxic drugs in hospitalized liver disease 
patients (10). For that reason, we designed this retrospec-
tive study to investigate the prescribing patterns of 
potentially hepatotoxic drugs (PHD) in a Brazilian cohort of 
patients with CLD, and the demographic, clinical and 
laboratory characteristics.
Patients and methods
This retrospective study was conducted in adults (18 years 
or older), of both sex, with liver disease (cirrhotic or not) 
evaluated by hepatology department, at the Hospital de 
Clínicas of Porto Alegre, south Brazil, from January 2016 
through December 2018. This study was approved by the 
Hospital de Clínicas of Porto Alegre Ethics Committee, 
and informed consent for review of medical records was 
not needed. We excluded patients with organ transplants 
(except isolated liver), carriers of human immunodefi-
ciency virus and patients with missing data from electronic 
medical records. The acute-on-chronic liver failure (ACLF) 
was defined as recommendations of the Asian Pacific 
Association (11).
We access the patient's gender and age, length of stay 
and reason for hospitalization, sector of prescription in the 
hospital and class of drugs used, describing the most 
frequents. Antihypertensives, antianginals and antiarrhy-
thmic were considered in the cardiovascular class. 
Anxiolytics, antidepressants and anticonvulsants were 
included in the class of neuromodulators. If the patient was 
cirrhotic, the etiology, Child Pugh and the model for end-
stage liver disease (MELD) were analyzed, as well as 
cirrhosis decompensation at the moment of hospitali-
zation. We described values of gamma-glutamyl 
transferase (GGT), alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), total bilirubin, creatinine and prothrombin time 
present in medical records before and after hospitalization 
and their highest values during it. The presence or 
absence of death during hospitalization was also 
analyzed.
Statistical analysis 
The qualitative variables are shown in terms of absolute 
and relative frequencies in percentage. The continuous 
ones are expressed in terms of summary measures, 
mainly median with interquartile range or mean +/- EE 
(standard error). In the case of continuous variables, the 
normality test was studied with the Kolmogorov-Smirnov 
test. When the assumption was not fulfilled, it was 
analyzed with the non-parametric Friedman test for the 
comparison between three times. The association study 
between qualitative variables was carried out with Chi 
square test or Fisher's exact test in the cases of expected 
cells smaller than 5. In the case of statistical association, 
the corresponding association strength is calculated - 
Odds Ratio with its 95% Confidence Interval (CI). Non-
parametric Mann-Whitney test was used to calculate 
differences between independent groups for each 
continuous variable of interest. We worked with an alpha 
significance value of 0.05. Statistical analysis has been 
performed with STATA v.12.0 software.
Results
In the analyzed period, 931 patients with CLD were 
hospitalized and a total of 291 patients (31.3%) were 
exposed to hepatotoxic drugs during their hospitalization, 
in the period from January 2016 through December 2018 
at the Hospital de Clínicas of Porto Alegre. Of those, 53% 
were men, with an average age of 60 years. Cirrhosis were 
present in 83% of patients, and 3% presented ACLF. The 
most frequent reason for hospitalization was due to 
decompensated cirrhosis (46.7%), followed by hepatoce-
llular carcinoma (18.6%).  
The most frequent etiology of liver damage was hepatitis C 
(41.2%) followed by alcohol (13.4%), hepatitis C/alcohol 
(11.7%), non-alcoholic fatty liver disease (5.8%), hepatitis 
B (3.8%), cholestatic disease (3.4%) and autoimmune 
hepatitis (1.4%). In relation to the Child-Pugh score, the 
data was lacking for 54.6% of the patients. For those who 
had data, 29.5% (39 patients) were from group A, 43.2% 
(57 patients) from group B and 27.3% (36 patients) from 
group C. Information about variables used to calculate 
MELD score was available in 103/291. MELD ≤15 were 
present in 64 patients, MELD 16-30 in 33 patients, and 
MELD 31-46 in 6 patients. Regarding the cause of liver 
disease decompensation, 121 patients (41.6%) had 
ascites, 45 patients (15.5%) had gastrointestinal bleeding, 
29 patients (10.0%) had spontaneous bacterial peritonitis, 
77 patients (26.5%) had hepatic encephalopathy and 97 
patients (33.3%) showed loss of kidney function. Liver 
disease without cirrhosis were 47 patients (17%) (table 1). 
The most frequent sector of medication prescription was in 
the gastroenterology / hepatology department (48.8%) 
followed by emergency/ intensive care unit (28.5%). The 
most often prescribed PHD were antibiotics (67.7%), 
followed by cardiovascular drugs (34.4%), anesthetics 
(19.9%), non-steroidal anti-inflammatory drugs (NSAIDs) 
(8,2%), antifungal (7.2%), antiviral (6.5%), statins (6.2%), 
antithyroid (4.8), tuberculostatic drugs (1.4%) and 
antineoplastic agents (1.4%). (Table 1)
In regard to antibiotics, the average liver enzymes peak 
post-PHD exposition was 2.7 times upper limit of normality 
(ULN) of AST, 2.4 times ULN ALT, two times ULN of AP, two 
times ULN of GGT and 2.5 times of total bilirubin. About 
cardiovascular drugs, the average was five times ULN of 
AST, 3.7 times ULN of ALT, 3 times ULN of AP, 2.3 times 
ULN of GGT and 3.1 times ULN of total bilirubin. 
Concerning neuromodulators, the average laboratory 
post-PHD exposition was 3.4 times ULN of AST, 3 times 
Characteristics N N %
Gender Woman 136 46.7
Men 155 53.3
Clinical decompensation Ascites 121 41.6
Digestive Bleeding 45 15.5
Spontaneous Bacterial Peritonitis 29 10
Impaired kidney function 97 33.3
Hepatic Encephalopathy (HE) 77 26.5
ACLF 9 3.1
Cirrhosis 244 83.8
Etiology of Chronic Liver disease HCV 120 41.2




Cholestatic disease 10 3.4
Autoimmune hepatitis 4 1,4
HCV + NAFLD 1 0.3
Other 36 12.3
No data 14 4.8











Cause of hospitalization Decompensated cirrhosis 136 46.7
HCC 54 18.6
Others 101 34.7
Department of diagnostic Emergency/ICU 83 28.5
Hospitalization GAS/HEP 142 48.8
Hospitalization /Others 66 22.7
Death 65 22
Table 1. Baseline characteristics of all patients, cause of chronic liver disease and drugs
ACLF, acute-on-chronic liver failure; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, Non-alcoholic fatty liver 
disease; HCC hepatocellular carcinoma; GAS/HEP hepatology; NSAIDs, nonsteroidal anti-inflammatory drugs; ICU, 
intensive care unit.
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short time span (hours to days), while idiosyncratic is 
usually not dose-related, and has a longer latency period 
(3).
Cirrhosis and chronic liver disease (CLD) not necessarily 
increases the risk of developing DILI (7, 8), however it is 
known based on systematic review of cohort studies that 
chronic hepatitis B and C are  risk factors for DILI caused 
by anti- human immunodeficiency virus and anti-
tuberculostatic therapy (9). Furthermore, DILI in patients 
with underlying liver disease arouse higher mortality (4). In 
cirrhotic patients most medications have not been 
thoroughly studied and specific prescribing information is 
often lacking; in those patients lower doses of medication 
are generally recommended based on pharmacokinetic 
change, despite limited data also in that subject (10). Acute 
hepatic lesion caused by drugs has been reported 
between 2% and 10% of patients hospitalized for jaundice 
(8). Hospitalized CLD patients are at high risk for 
developing DILI, however among those patients there is 
scant information on the pattern of medical prescription 
(10).
The diagnostic of DILI is a challenge for physicians, due 
the heterogeneous phenotypes (mild increase of liver 
enzymes (cholestatic, hepatocellular and mixed) to acute 
liver failure (ALF), absence of specific biomarkers and the 
need for diagnosis exclusion) (9). The greatest difficulty in 
research on DILI in patients with underlying liver disease is 
the distinction between additional liver injury caused by a 
medicine or progression of the underlying liver disease. 
Add to that the is sparing information on the pattern of 
potential hepatotoxic drugs in hospitalized liver disease 
patients (10). For that reason, we designed this retrospec-
tive study to investigate the prescribing patterns of 
potentially hepatotoxic drugs (PHD) in a Brazilian cohort of 
patients with CLD, and the demographic, clinical and 
laboratory characteristics.
Patients and methods
This retrospective study was conducted in adults (18 years 
or older), of both sex, with liver disease (cirrhotic or not) 
evaluated by hepatology department, at the Hospital de 
Clínicas of Porto Alegre, south Brazil, from January 2016 
through December 2018. This study was approved by the 
Hospital de Clínicas of Porto Alegre Ethics Committee, 
and informed consent for review of medical records was 
not needed. We excluded patients with organ transplants 
(except isolated liver), carriers of human immunodefi-
ciency virus and patients with missing data from electronic 
medical records. The acute-on-chronic liver failure (ACLF) 
was defined as recommendations of the Asian Pacific 
Association (11).
We access the patient's gender and age, length of stay 
and reason for hospitalization, sector of prescription in the 
hospital and class of drugs used, describing the most 
frequents. Antihypertensives, antianginals and antiarrhy-
thmic were considered in the cardiovascular class. 
Anxiolytics, antidepressants and anticonvulsants were 
included in the class of neuromodulators. If the patient was 
cirrhotic, the etiology, Child Pugh and the model for end-
stage liver disease (MELD) were analyzed, as well as 
cirrhosis decompensation at the moment of hospitali-
zation. We described values of gamma-glutamyl 
transferase (GGT), alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), total bilirubin, creatinine and prothrombin time 
present in medical records before and after hospitalization 
and their highest values during it. The presence or 
absence of death during hospitalization was also 
analyzed.
Statistical analysis 
The qualitative variables are shown in terms of absolute 
and relative frequencies in percentage. The continuous 
ones are expressed in terms of summary measures, 
mainly median with interquartile range or mean +/- EE 
(standard error). In the case of continuous variables, the 
normality test was studied with the Kolmogorov-Smirnov 
test. When the assumption was not fulfilled, it was 
analyzed with the non-parametric Friedman test for the 
comparison between three times. The association study 
between qualitative variables was carried out with Chi 
square test or Fisher's exact test in the cases of expected 
cells smaller than 5. In the case of statistical association, 
the corresponding association strength is calculated - 
Odds Ratio with its 95% Confidence Interval (CI). Non-
parametric Mann-Whitney test was used to calculate 
differences between independent groups for each 
continuous variable of interest. We worked with an alpha 
significance value of 0.05. Statistical analysis has been 
performed with STATA v.12.0 software.
Results
In the analyzed period, 931 patients with CLD were 
hospitalized and a total of 291 patients (31.3%) were 
exposed to hepatotoxic drugs during their hospitalization, 
in the period from January 2016 through December 2018 
at the Hospital de Clínicas of Porto Alegre. Of those, 53% 
were men, with an average age of 60 years. Cirrhosis were 
present in 83% of patients, and 3% presented ACLF. The 
most frequent reason for hospitalization was due to 
decompensated cirrhosis (46.7%), followed by hepatoce-
llular carcinoma (18.6%).  
The most frequent etiology of liver damage was hepatitis C 
(41.2%) followed by alcohol (13.4%), hepatitis C/alcohol 
(11.7%), non-alcoholic fatty liver disease (5.8%), hepatitis 
B (3.8%), cholestatic disease (3.4%) and autoimmune 
hepatitis (1.4%). In relation to the Child-Pugh score, the 
data was lacking for 54.6% of the patients. For those who 
had data, 29.5% (39 patients) were from group A, 43.2% 
(57 patients) from group B and 27.3% (36 patients) from 
group C. Information about variables used to calculate 
MELD score was available in 103/291. MELD ≤15 were 
present in 64 patients, MELD 16-30 in 33 patients, and 
MELD 31-46 in 6 patients. Regarding the cause of liver 
disease decompensation, 121 patients (41.6%) had 
ascites, 45 patients (15.5%) had gastrointestinal bleeding, 
29 patients (10.0%) had spontaneous bacterial peritonitis, 
77 patients (26.5%) had hepatic encephalopathy and 97 
patients (33.3%) showed loss of kidney function. Liver 
disease without cirrhosis were 47 patients (17%) (table 1). 
The most frequent sector of medication prescription was in 
the gastroenterology / hepatology department (48.8%) 
followed by emergency/ intensive care unit (28.5%). The 
most often prescribed PHD were antibiotics (67.7%), 
followed by cardiovascular drugs (34.4%), anesthetics 
(19.9%), non-steroidal anti-inflammatory drugs (NSAIDs) 
(8,2%), antifungal (7.2%), antiviral (6.5%), statins (6.2%), 
antithyroid (4.8), tuberculostatic drugs (1.4%) and 
antineoplastic agents (1.4%). (Table 1)
In regard to antibiotics, the average liver enzymes peak 
post-PHD exposition was 2.7 times upper limit of normality 
(ULN) of AST, 2.4 times ULN ALT, two times ULN of AP, two 
times ULN of GGT and 2.5 times of total bilirubin. About 
cardiovascular drugs, the average was five times ULN of 
AST, 3.7 times ULN of ALT, 3 times ULN of AP, 2.3 times 
ULN of GGT and 3.1 times ULN of total bilirubin. 
Concerning neuromodulators, the average laboratory 
post-PHD exposition was 3.4 times ULN of AST, 3 times 
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Others 101 34.7
Department of diagnostic Emergency/ICU 83 28.5
Hospitalization GAS/HEP 142 48.8
Hospitalization /Others 66 22.7
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Table 1. Baseline characteristics of all patients, cause of chronic liver disease and drugs
ACLF, acute-on-chronic liver failure; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, Non-alcoholic fatty liver 
disease; HCC hepatocellular carcinoma; GAS/HEP hepatology; NSAIDs, nonsteroidal anti-inflammatory drugs; ICU, 
intensive care unit.
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ULN of ALT, 1.2 times ULN of AP, 1.6 times ULN of GGT 
and 2 times ULN of total bilirubin. With regard to 
anesthetics drugs the average laboratory post-PHD 
exposition was 4.1 times ULN of AST, 3.6 times ULN of 
ALT, 3.6 times ULN of AP, 2.4 times ULN of GGT and 2.5 
times ULN of total bilirubin; and for NSAIDs 2.8 times ULN 
of AST, 4.9 times ULN of ALT, 1.62 times ULN of AP, 2.6 
times ULN of GGT and 3.1 times ULN of total bilirubin. 
Figures 1 to 4 show the peak of laboratory abnormalities 
reached with the use of antibiotics, cardiovascular drugs, 
neuromodulators and anesthetics respectively.
Figure 1. Variation of mean values of liver 
biochemistries in patients who used Antibiotics
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 2. Variation of mean values of liver 
biochemistries in patients who used Cardiovascular 
drugs
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Regarding the group that received amoxicillin clavulanic, 
the average age and time of hospitalization were 56 years 
and 19 days respectively. Still regarding this agent, figure 5 
shows the peak of laboratory abnormalities reached with 
the use of this drug. 
After drugs exposure, 113 patients (38,8%) had significant 
elevated liver enzymes. No statistically significant 
association was established between elevations of ALT 
(elevation of ≥5 ULN) or ALP (≥2 ULN) and accompanying 
elevations in concentrations of GGT, as elevation of ≥5 
ULN ALT or ≥2 ULN ALP and the demographic characteris-
Figure 3. Variation of mean values of liver 
biochemistries in patients who used 
Neuromodulators agents
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 4. Variation of mean values of liver 
biochemistries in patients who used Nonsteroidal 
anti-inflammatory drugs
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 5. Variation of mean values of liver 
biochemistries in patients who used Amoxicillin-
Clavulanate.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
tics of the patients, the Child Pugh or the frequency of the 
group of drugs. A total of 67 patients (22%) died. The 
presence of ascites, hepatic encephalopathy and impaired 
renal function were associated with death (p-value< 0.05). 
Of the 82 patients who received the antibiotic cefepime, 33 
died (p-value< 0.001) and, of the 48 who received 
amoxicillin clavulanic 11 died (p-value 0.849).
Discussion
The drug therapy in patients with CLD is complex 
especially in cirrhotic  patients due to the pathophysio-
logical changes associated with the disease that alter the 
pharmacokinetics of drugs.(8) Patients with liver cirrhosis 
require close monitoring and dose adjustment to ensure 
rational use of medicines, to avoid the risk of DILI and other 
medicine-related problems.
This study described PHD utilization in a large cohort of 
CLD patients in a tertiary university hospital. We 
demonstrated that many patients with CLD received a 
potentially unsafe drugs during the study period (31.3%). 
This indicates the great magnitude of the results and 
illustrates the disregard for DILI in this population.
As stated at American College of Gastroenterology 
Clinical Guideline the use of potentially hepatotoxic drugs 
in patients with underlying liver disease should be based in 
risk versus benefit of the proposed therapy, with a case-by-
case analysis (1). The guideline recommends advising the 
patients for cholestasis symptoms and abdominal pain; 
also monitor serum liver biochemistries at 4 – 6 week 
intervals, especially during the initial 6 months of treatment 
(1)(9). In our study, several drugs with hepatotoxic 
potential were used, such as NSAIDs, amiodarone and 
amoxi-clavulanate, even though other drugs with less 
hepatotoxic potential could have been used. This shows 
that the risk-benefit assessment was not always conside-
red.
However the remaining drugs considered as potentially 
unsafe, such as betablockers, vasoactive drugs, and other  
antibiotics are life-saving drugs, particularly in patients 
admitted for decompensated cirrhosis. Thus, although it is 
very interesting to know the rate of DILI, the discussion of 
whether these drugs could have been avoided seems to 
be much more profound. Similarly, when considering 
admitted patients with severe underlying liver disease, 
perhaps confounders such as sepsis among others should 
be taken into account when evaluating transaminases and 
the impact of prescribed drugs.
Sex does not appear to be a risk for DILI (5, 12), however 
female patients with DILI seems to have a higher risk of 
ALF progression (13). Incidence of DILI appears to 
increase with age, this is also paralleled by an increase in 
medication use, suggesting that age per se might not be a 
risk for DILI (14). The Latin American DILI Network 
(LATINDILIN), a consort ium of Latin American 
hepatologists that aim identification and characterization 
of DILI cases in Central and South America, described  an 
average age of 50 years (11‐91 years), and 61% female 
(15). A  prospective study in a tertiary Egyptian hospital 
analyzed patients with CLD who presented DILI; of those 
66.1% were men, and the mean age was 46.4 years ± 12.3 
(16). In our study, median age was 60 years (51-66) and 
53.3% of the patients were men.
Hepatitis C was present in 41.2% of patients, supported by 
other studies that show this infection as one of the main 
causes of CLD worldwide (17,18,19). In addition, when 
treatment of C virus with direct drugs agents is being 
carried out, it is necessary to take into account not only the 
possibility of hepatotoxicity of other drugs used during 
treatment, but also the risk of drug interaction (20).
It is interesting to note that 113 (38%) patients already had 
abnormal liver exams before starting treatment with 
hepatotoxic drugs and 88.5% of these patients were 
cirrhotic. Although we cannot adjudicate the hepatic 
changes due to these drugs, this suggests that attention is 
missing prescribe potentially hepatotoxic drugs in 
hospitalized CLD patients.
 Most patients were cirrhotic, and ascites was present in 
41.6% of them. Cirrhosis can affects drug absorption, 
distribution, bioavailability, cytochrome P450 metabolism 
and hepatic and renal clearance mechanisms, resulting in 
pharmacodynamic consequences (21). The presence of 
ascites can affect the volume distribution of drugs, 
bioavailability and elimination half‐life (22).
The most used drug class in our study was antibiotics 
(67.7% of patients). In LATIDIN's DILI records, the most 
frequent drug classes were anti‐infectives (32%), 
musculoskeletal agents (14%), antineoplastics (8.6%), 
sex hormones (8.2%), and central nervous system drugs 
(8.2%) whereas in the Spanish DILI Registry, 
anti‐infectives (38%), central nervous system drugs 
(13%), musculoskeletal agents (11%), and cardiovascular 
drugs (10%) were the most represented. As for the isolated 
agent, amoxicillin-clavulanate was the most frequent in 
both records (15).
Amoxicillin clavulanate was used in 47 patients in our 
study. This drug is usually associated with a cholestatic 
pattern caused mostly by the clavulanic component, 
usually affects women, aged > 65 years and with previous 
report of this drug (24). Presentations regarding the use of 
this agent could be mild or severe, leading to ALF or urgent 
liver transplantation (25). The study by Lucena et al. 
suggests that amoxicillin clavulanate might be the most 
common cause of unpredictable hepatotoxicity in adults in 
Spain. The main pattern of lesion was hepatocellular, with 
age as the factor associated to development of 
cholestatic/mixed type of injury (26).
It is interesting that 47 patients received amoxicillin 
clavulanate, taking into account that its hepatotoxic 
potential is well known (category A), which implies more 
than 50 published cases. We believe that therapeutic 
alternatives with a lower hepatotoxic profile could and can 
be considered.
Cefepime, a fourth-generation cephalosporin, was 
another frequently prescribed antibiotic (82 patients). The 
cephalosporins is general associated with few 
hepatotoxicity cases, and only rare instances of DILI due 
to these agents have been published (27). The typical 
case of liver injury due to cephalosporins is self-limited 
cholestatic hepatitis with mild immunoallergenic features, 
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ULN of ALT, 1.2 times ULN of AP, 1.6 times ULN of GGT 
and 2 times ULN of total bilirubin. With regard to 
anesthetics drugs the average laboratory post-PHD 
exposition was 4.1 times ULN of AST, 3.6 times ULN of 
ALT, 3.6 times ULN of AP, 2.4 times ULN of GGT and 2.5 
times ULN of total bilirubin; and for NSAIDs 2.8 times ULN 
of AST, 4.9 times ULN of ALT, 1.62 times ULN of AP, 2.6 
times ULN of GGT and 3.1 times ULN of total bilirubin. 
Figures 1 to 4 show the peak of laboratory abnormalities 
reached with the use of antibiotics, cardiovascular drugs, 
neuromodulators and anesthetics respectively.
Figure 1. Variation of mean values of liver 
biochemistries in patients who used Antibiotics
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 2. Variation of mean values of liver 
biochemistries in patients who used Cardiovascular 
drugs
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Regarding the group that received amoxicillin clavulanic, 
the average age and time of hospitalization were 56 years 
and 19 days respectively. Still regarding this agent, figure 5 
shows the peak of laboratory abnormalities reached with 
the use of this drug. 
After drugs exposure, 113 patients (38,8%) had significant 
elevated liver enzymes. No statistically significant 
association was established between elevations of ALT 
(elevation of ≥5 ULN) or ALP (≥2 ULN) and accompanying 
elevations in concentrations of GGT, as elevation of ≥5 
ULN ALT or ≥2 ULN ALP and the demographic characteris-
Figure 3. Variation of mean values of liver 
biochemistries in patients who used 
Neuromodulators agents
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 4. Variation of mean values of liver 
biochemistries in patients who used Nonsteroidal 
anti-inflammatory drugs
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
Figure 5. Variation of mean values of liver 
biochemistries in patients who used Amoxicillin-
Clavulanate.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FA, 
fosfatase alcalina; GGT, gamma glutamyl transpeptidase; BT, bilirrubina 
total.
tics of the patients, the Child Pugh or the frequency of the 
group of drugs. A total of 67 patients (22%) died. The 
presence of ascites, hepatic encephalopathy and impaired 
renal function were associated with death (p-value< 0.05). 
Of the 82 patients who received the antibiotic cefepime, 33 
died (p-value< 0.001) and, of the 48 who received 
amoxicillin clavulanic 11 died (p-value 0.849).
Discussion
The drug therapy in patients with CLD is complex 
especially in cirrhotic  patients due to the pathophysio-
logical changes associated with the disease that alter the 
pharmacokinetics of drugs.(8) Patients with liver cirrhosis 
require close monitoring and dose adjustment to ensure 
rational use of medicines, to avoid the risk of DILI and other 
medicine-related problems.
This study described PHD utilization in a large cohort of 
CLD patients in a tertiary university hospital. We 
demonstrated that many patients with CLD received a 
potentially unsafe drugs during the study period (31.3%). 
This indicates the great magnitude of the results and 
illustrates the disregard for DILI in this population.
As stated at American College of Gastroenterology 
Clinical Guideline the use of potentially hepatotoxic drugs 
in patients with underlying liver disease should be based in 
risk versus benefit of the proposed therapy, with a case-by-
case analysis (1). The guideline recommends advising the 
patients for cholestasis symptoms and abdominal pain; 
also monitor serum liver biochemistries at 4 – 6 week 
intervals, especially during the initial 6 months of treatment 
(1)(9). In our study, several drugs with hepatotoxic 
potential were used, such as NSAIDs, amiodarone and 
amoxi-clavulanate, even though other drugs with less 
hepatotoxic potential could have been used. This shows 
that the risk-benefit assessment was not always conside-
red.
However the remaining drugs considered as potentially 
unsafe, such as betablockers, vasoactive drugs, and other  
antibiotics are life-saving drugs, particularly in patients 
admitted for decompensated cirrhosis. Thus, although it is 
very interesting to know the rate of DILI, the discussion of 
whether these drugs could have been avoided seems to 
be much more profound. Similarly, when considering 
admitted patients with severe underlying liver disease, 
perhaps confounders such as sepsis among others should 
be taken into account when evaluating transaminases and 
the impact of prescribed drugs.
Sex does not appear to be a risk for DILI (5, 12), however 
female patients with DILI seems to have a higher risk of 
ALF progression (13). Incidence of DILI appears to 
increase with age, this is also paralleled by an increase in 
medication use, suggesting that age per se might not be a 
risk for DILI (14). The Latin American DILI Network 
(LATINDILIN), a consort ium of Latin American 
hepatologists that aim identification and characterization 
of DILI cases in Central and South America, described  an 
average age of 50 years (11‐91 years), and 61% female 
(15). A  prospective study in a tertiary Egyptian hospital 
analyzed patients with CLD who presented DILI; of those 
66.1% were men, and the mean age was 46.4 years ± 12.3 
(16). In our study, median age was 60 years (51-66) and 
53.3% of the patients were men.
Hepatitis C was present in 41.2% of patients, supported by 
other studies that show this infection as one of the main 
causes of CLD worldwide (17,18,19). In addition, when 
treatment of C virus with direct drugs agents is being 
carried out, it is necessary to take into account not only the 
possibility of hepatotoxicity of other drugs used during 
treatment, but also the risk of drug interaction (20).
It is interesting to note that 113 (38%) patients already had 
abnormal liver exams before starting treatment with 
hepatotoxic drugs and 88.5% of these patients were 
cirrhotic. Although we cannot adjudicate the hepatic 
changes due to these drugs, this suggests that attention is 
missing prescribe potentially hepatotoxic drugs in 
hospitalized CLD patients.
 Most patients were cirrhotic, and ascites was present in 
41.6% of them. Cirrhosis can affects drug absorption, 
distribution, bioavailability, cytochrome P450 metabolism 
and hepatic and renal clearance mechanisms, resulting in 
pharmacodynamic consequences (21). The presence of 
ascites can affect the volume distribution of drugs, 
bioavailability and elimination half‐life (22).
The most used drug class in our study was antibiotics 
(67.7% of patients). In LATIDIN's DILI records, the most 
frequent drug classes were anti‐infectives (32%), 
musculoskeletal agents (14%), antineoplastics (8.6%), 
sex hormones (8.2%), and central nervous system drugs 
(8.2%) whereas in the Spanish DILI Registry, 
anti‐infectives (38%), central nervous system drugs 
(13%), musculoskeletal agents (11%), and cardiovascular 
drugs (10%) were the most represented. As for the isolated 
agent, amoxicillin-clavulanate was the most frequent in 
both records (15).
Amoxicillin clavulanate was used in 47 patients in our 
study. This drug is usually associated with a cholestatic 
pattern caused mostly by the clavulanic component, 
usually affects women, aged > 65 years and with previous 
report of this drug (24). Presentations regarding the use of 
this agent could be mild or severe, leading to ALF or urgent 
liver transplantation (25). The study by Lucena et al. 
suggests that amoxicillin clavulanate might be the most 
common cause of unpredictable hepatotoxicity in adults in 
Spain. The main pattern of lesion was hepatocellular, with 
age as the factor associated to development of 
cholestatic/mixed type of injury (26).
It is interesting that 47 patients received amoxicillin 
clavulanate, taking into account that its hepatotoxic 
potential is well known (category A), which implies more 
than 50 published cases. We believe that therapeutic 
alternatives with a lower hepatotoxic profile could and can 
be considered.
Cefepime, a fourth-generation cephalosporin, was 
another frequently prescribed antibiotic (82 patients). The 
cephalosporins is general associated with few 
hepatotoxicity cases, and only rare instances of DILI due 
to these agents have been published (27). The typical 
case of liver injury due to cephalosporins is self-limited 
cholestatic hepatitis with mild immunoallergenic features, 
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Use of potentially hepatotoxic drugs in patients with liver disease
if it arises, 1 to 3 weeks after starting therapy, which 
sometimes occurs after a single parenteral dose. (28)
Cefepime is considered category D, with one to three 
cases of hepatotoxicity reported in the literature. Liao et al, 
describe a rare case of cefepime induced cholestasic liver 
injury. (29) 
 In the DILIN study carried out in the United States, 10% of 
individuals with DILI had pre-existing CLD, most of whom 
had hepatitis C, a mean age of 52 years, mostly women, 
mean ALT 689 U/l, AP 284 U/l, total bilirubin 13 mg/dl, 
international standardized ratio 1.8. Among agents used 
that cause DILI in this population the most frequent were 
antimicrobials (51%), cardiovascular agents (7%), 
antineoplastic agents (6%), and central nervous system 
agents (4.5%). (4)
As in the previously cited article, in this study the second 
most widely used class of drugs were cardiovascular 
(34.4%). As a class, angiotensin-converting enzyme 
inhibitors in patients with cirrhosis produce adverse effects 
mainly related to hyperkalemia and worsening of renal 
function. In the study by Franz et al. 19% of patients 
treated with an angiotensin converting enzyme inhibitor 
experienced adverse effects. In that same study, of the 
146 patients taking beta-blockers, 7 patients suffered 
adverse effects. (23).
In our study, NSAID were used in 8.2% of patients.  
NSAIDs are a class of drugs largely used, often self-
managed in the indications and dosages, not always 
requiring a medical prescription, leading to a high risk of 
adverse effects, including the risk of liver injury (30). 
NSAIDs should be avoided in cirrhotic patients, especially 
those with hydrosaline retention, because they inhibit the 
synthesis of renal prostaglandins (essential for the 
maintenance of decreased renal perfusion by activation of 
vasoconstrictor systems) and may precipitate functional 
renal failure. Since kidney failure can lead to fatal 
compliments in a cirrhotic patient, NSAIDs should not be 
the first choice in patients with ALF (30). An Italian 
multicenter study found that the annual incidence of DILI 
induced by NSAIDs was two cases per 100  000 
inhabitants with odd rate of 1.69 [95% CI , 1.21–2.37], with 
nimesulide and ibuprofen associated to a statistically 
significant increased risk of liver damage, odd ratio of 2.10 
(95% CI, 1.28–3.47) and 1.92 (95% CI, 1.13–3.26) 
respectively (31). 
DILI can have several presentations from mild increase of 
liver enzymes to ALF and death (9). Chalasani et al. 
demonstrated higher mortality between patients with DILI 
and pre-existing liver disease vs healthy patients (16% vs 
5.2%; P < 0.001) (4). In our study, 22% of patients died 
during hospitalization; of these, 28.4% used antibiotics (p 
<0.001), and 47.6% antifungal (p 0.004).  DILI as a cause 
of ACLF represents 46.5% mortality (31). In our study 9 
patients who had ACLF 6 died (66.7%), the age of these 
patients ranged between 51-70, being decompensation of 
cirrhosis the cause in 3 patients and infection in the others.
This study has certain strengths that must be emphasized: 
this is one of the few studies at national level where the 
prescription of hepatotoxic drugs in patients admitted to a 
tertiary hospital was evaluated. The results have shown 
that a large number of patients received potentially 
hepatotoxic drugs that could have been avoided. On the 
other hand, there are limitations: this is a retrospective 
study, it is not possible to safely infer the causal 
relationship between the drug used and laboratory 
changes and the presence of mortality, and there may be 
other confounding factors. 
Attributing to the drugs the elevation in liver enzymes is 
misleading as in absence of a proper adjudication process, 
liver enzymes can be elevated in these patients because 
many other causes including infection, liver ischemia in the 
setting of bleeding or acute on chronic liver failure. 
We did not always have access to some important data 
such as the reason for the indication of each drug, the 
latency time and its relationship with changes in the liver 
enzymes. Furthermore, ALT (≥5 ULN) or ALP (≥2 ULN) 
(with accompanying elevations in concentrations of GGT), 
were considered significant abnormalities without 
considering in patients with CLD what their previous 
baseline values were, so this could have overestimated 
the group of patients with altered liver enzymes.
Conclusion
The present study expands current knowledge of 
prescribing patterns for associated conditions in patients 
with underlying liver disease. Potential hepatotoxic drugs 
prescription is frequent in patients with CLD even in a 
tertiary university hospital, exposing these patients to 
additional risk.  The risk for DILI development through the 
use of PHD in patients with liver disease is the subject of 
continuous controversy. In patients with liver disease, 
before prescribing any drugs it is crucial to assess the risk 
of DILI. Is essential to search for less hepatotoxic drugs, 
and when the potentially hepatotoxic medicine needs to be 
used, continuous laboratory monitoring is mandatory.  
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Use of potentially hepatotoxic drugs in patients with liver disease
if it arises, 1 to 3 weeks after starting therapy, which 
sometimes occurs after a single parenteral dose. (28)
Cefepime is considered category D, with one to three 
cases of hepatotoxicity reported in the literature. Liao et al, 
describe a rare case of cefepime induced cholestasic liver 
injury. (29) 
 In the DILIN study carried out in the United States, 10% of 
individuals with DILI had pre-existing CLD, most of whom 
had hepatitis C, a mean age of 52 years, mostly women, 
mean ALT 689 U/l, AP 284 U/l, total bilirubin 13 mg/dl, 
international standardized ratio 1.8. Among agents used 
that cause DILI in this population the most frequent were 
antimicrobials (51%), cardiovascular agents (7%), 
antineoplastic agents (6%), and central nervous system 
agents (4.5%). (4)
As in the previously cited article, in this study the second 
most widely used class of drugs were cardiovascular 
(34.4%). As a class, angiotensin-converting enzyme 
inhibitors in patients with cirrhosis produce adverse effects 
mainly related to hyperkalemia and worsening of renal 
function. In the study by Franz et al. 19% of patients 
treated with an angiotensin converting enzyme inhibitor 
experienced adverse effects. In that same study, of the 
146 patients taking beta-blockers, 7 patients suffered 
adverse effects. (23).
In our study, NSAID were used in 8.2% of patients.  
NSAIDs are a class of drugs largely used, often self-
managed in the indications and dosages, not always 
requiring a medical prescription, leading to a high risk of 
adverse effects, including the risk of liver injury (30). 
NSAIDs should be avoided in cirrhotic patients, especially 
those with hydrosaline retention, because they inhibit the 
synthesis of renal prostaglandins (essential for the 
maintenance of decreased renal perfusion by activation of 
vasoconstrictor systems) and may precipitate functional 
renal failure. Since kidney failure can lead to fatal 
compliments in a cirrhotic patient, NSAIDs should not be 
the first choice in patients with ALF (30). An Italian 
multicenter study found that the annual incidence of DILI 
induced by NSAIDs was two cases per 100  000 
inhabitants with odd rate of 1.69 [95% CI , 1.21–2.37], with 
nimesulide and ibuprofen associated to a statistically 
significant increased risk of liver damage, odd ratio of 2.10 
(95% CI, 1.28–3.47) and 1.92 (95% CI, 1.13–3.26) 
respectively (31). 
DILI can have several presentations from mild increase of 
liver enzymes to ALF and death (9). Chalasani et al. 
demonstrated higher mortality between patients with DILI 
and pre-existing liver disease vs healthy patients (16% vs 
5.2%; P < 0.001) (4). In our study, 22% of patients died 
during hospitalization; of these, 28.4% used antibiotics (p 
<0.001), and 47.6% antifungal (p 0.004).  DILI as a cause 
of ACLF represents 46.5% mortality (31). In our study 9 
patients who had ACLF 6 died (66.7%), the age of these 
patients ranged between 51-70, being decompensation of 
cirrhosis the cause in 3 patients and infection in the others.
This study has certain strengths that must be emphasized: 
this is one of the few studies at national level where the 
prescription of hepatotoxic drugs in patients admitted to a 
tertiary hospital was evaluated. The results have shown 
that a large number of patients received potentially 
hepatotoxic drugs that could have been avoided. On the 
other hand, there are limitations: this is a retrospective 
study, it is not possible to safely infer the causal 
relationship between the drug used and laboratory 
changes and the presence of mortality, and there may be 
other confounding factors. 
Attributing to the drugs the elevation in liver enzymes is 
misleading as in absence of a proper adjudication process, 
liver enzymes can be elevated in these patients because 
many other causes including infection, liver ischemia in the 
setting of bleeding or acute on chronic liver failure. 
We did not always have access to some important data 
such as the reason for the indication of each drug, the 
latency time and its relationship with changes in the liver 
enzymes. Furthermore, ALT (≥5 ULN) or ALP (≥2 ULN) 
(with accompanying elevations in concentrations of GGT), 
were considered significant abnormalities without 
considering in patients with CLD what their previous 
baseline values were, so this could have overestimated 
the group of patients with altered liver enzymes.
Conclusion
The present study expands current knowledge of 
prescribing patterns for associated conditions in patients 
with underlying liver disease. Potential hepatotoxic drugs 
prescription is frequent in patients with CLD even in a 
tertiary university hospital, exposing these patients to 
additional risk.  The risk for DILI development through the 
use of PHD in patients with liver disease is the subject of 
continuous controversy. In patients with liver disease, 
before prescribing any drugs it is crucial to assess the risk 
of DILI. Is essential to search for less hepatotoxic drugs, 
and when the potentially hepatotoxic medicine needs to be 
used, continuous laboratory monitoring is mandatory.  
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Resumen
Introducción. En 2020-03-11 la Organización Mundial de la Salud categorizó COVID-19 como pandemia mundial. En 
Colombia, el departamento de Casanare declaró la emergencia sanitaria en 2020-03-16 y el Presidente de la 
República declaró emergencia económica, social y ecológica el 2020-03-17; cinco días después se confirmó el primer 
caso departamental. Objetivo. Indagar conocimientos, actitudes y prácticas (CAP) del departamento sobre COVID-
19. Métodos. Estudio descriptivo transversal de conocimientos, actitudes y prácticas (CAP) más caracterización 
sociodemográfica en población departamental (435.195 habitantes). Muestreo por municipio y grupo etario decenal 
mediante Statcalc, Epi-Info® 7.2.2.2. Captación de datos ejecutada con herramienta de Formularios Google vía redes 
sociales WhatsApp y Facebook. Análisis descriptivo con Epi Info™7.2.2.2 y Stata® 13. Resultados. Fueron 
diligenciadas en total 1.120 encuestas arrojando los siguientes resultados: Socio-demografía: 541(48,9%) eran 
residentes en Yopal, 779(69,6%) mujeres, edad 36±12 años, 919(82,1%) entre 20-49 años, 582(50,2%) 
casados/unión libre, 251(22,4%) se identificaron como trabajadores de la salud y 869 (77,6%) desempeñaban otras 
actividades, 565(50,4%) profesionales, de ellos, 157(27,8%) con posgrado, 113(10,1%) se reconocieron como 
pertenecientes a una etnia. Conocimientos: todos escucharon hablar de la enfermedad, 695 (62,1%) personas la 
describieron como una enfermedad viral/infecciosa; 1.077(96,2%) que se contagia por estornudos; para 155(13,8%) 
es una gripa; 965(86,2%) identificaron como signo temprano la tos leve y 334(29,8%) desconocían la ruta de atención. 
Actitudes: 657(58,6%) salieron por comida o trabajo en las últimas 24 horas; 985(85,5%) consideraron que la 
responsabilidad de prevención es de todos. Prácticas: 825(95,0%) manifestaron informarse por medio de la 
radio/televisión; 1.109 (99,0%) eligieron no salir de casa como la principal medida preventiva, 890(79,5%) no tuvieron 
consulta de salud en los últimos 30 días; ante la presencia de síntomas 896(80,0%) escogieron llamar a línea de 
atención; 809(72,2%) se debe estar en aislamiento/cuarentena para prevenir la enfermedad y 796 (71,1%) opinaron 
que la autoridad debe hacer Inspección/Vigilancia/Control y mantener el aislamiento. Discusión. La población mostró 
sobre COVID-19 conocimiento básico, buena actitud, posición cooperativa y exigencia a la autoridad. Se recomienda 
mantener/fortalecer las acciones de inspección, vigilancia y control (IVC) y la información, educación y comunicación 
a los ciudadanos.
Palabras clave: COVID-19, coronavirus, conocimientos, actitudes y práctica en salud, Colombia.
Abstract
Introduction. On 2020-03-11 World Health Organization classified COVID-19 as a pandemic. In Colombia, 
department of Casanare declared sanitary emergency on 2020-03-16 and the President of the Republic declared 
economical, social and ecological emergency on 2020-03-17; five days later the first case at department was 
confirmed. Objective. To survey knowledges, attitudes, and practices (KAP) on department's population. Methods. 
Descriptive cross-sectional on Knowledge-Attitudes-Practices (KAP) plus socio-demographic characterization on 
population (435.195 dwellers). Sampling by city and decennial age-group using Statcalc, Epi-Info® 7.2.2.2. Data 
gathering executed with Google Formularies tool through WhatsApp, Facebook social networks. Descriptive analysis 
with Epi Info™7.2.2.2 y Stata® 13. Results. Survey rendered 1.120 responses, resulting as follows: Socio-
demographic: 541 (48,9%) living at Yopal, 779 (69,6%) women; age 36 ± 12 yr-old; 919 (82,1%) were 20-49 yr-old, 582 
(50,2%) married/consensual union. By activity: 251 (22,4%) health workers, 869 (77,6%) others. Education: 565 
(50,4%) professionals, 157 of the latter postgraduates (27,8%); recognized ethnic group 113 (10,1%). Knowledges: 
description as viral/infectious disease 695 (62,1%); contagion through sneezing 1077 (96,2%); it's a cold 155 (13,8%); 
mild cough 965 (86,2%); attention route unknown 334 (29,8%). Attitudes: 657 (58,6%) left home for food, work or 
chores; prevention is for everyone, 985 (85,5%). Practices: 825 (95,0%) informated by TV/radio; main measure not 
leaving home 1.109 (99,0%); no health consultation in the last 30 days 890 (79,5%); to call attention line if symptoms 
896 (80,0%). Prevention by isolation/quarantine 809 (72,2%); authority must do inspection/vigilance/control 796 
(71,1%). Discussion. On COVID-19, population exhibited basic knowledge, good attitude and cooperative, even 
demanding position with local, regional Executive. It is recommended to maintain/strengthen Inspection / Vigilance / 
Control actions and Information / Education / Communication to citizens.
Keyword: COVID-19, coronavirus, health knowledge, attitudes, practice, Colombia.
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Introducción
En diciembre de 2019, las autoridades sanitarias de la 
ciudad de Wuhan, capital de la provincia de Hubei de la 
República Popular China, detectaron una agrupación de 
casos de neumonía de origen desconocido, ligados a la 
Plaza de Mercado de Mariscos del Sur de China (1). Tras 
pruebas y aislamientos, encontraron un virus de la gran 
familia de los coronavirus de tipo 2 -ß-coronavirus- 
causante de un síndrome respiratorio agudo severo, 
abreviado SARS-CoV-2 (del inglés severe acute 
respiratory syndrome coronavirus) luego denominado por 
la Organización Mundial de la Salud (OMS) como la 
enfermedad por coronavirus (Coronavirus Disease 2019, 
COVID-19) (2), responsable de la mayor crisis social y 
sanitaria desde la Primera Guerra Mundial (1), dado su 
veloz avance y su mortalidad, especialmente en adultos 
mayores, en países como Italia, España y Estados 
Unidos. En 2020-03-01, se registraban mundialmente 
3.000 muertes (3); a 2020-04-28, ya superaban 200 mil 
(4).
Virológicamente, el SARS-CoV-2 es similar en su 
estructura en un 79% a previos coronavirus (1, 5) 
causantes de las epidemias de síndrome respiratorio 
agudo severo (SARS-CoV) en 2002 (6) y el síndrome 
respiratorio de Oriente Medio (MERS-CoV) en 2012 (7). 
Los coronavirus, en su mayoría, son patógenos 
zoonóticos que han sido detectados en mercados donde 
animales vivos tan diversos como serpientes, aves de 
corral, pangolines o murciélagos son sacrificados para 
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drug-induced liver injury case-control study in Italy. Br J 
Clin Pharmacol. 2016; 82(1): 238-48.
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